Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementBCBS Rhode Island Back Pain Coverage Update | Open…
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Minimally Invasive Procedures for Back Pain

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and medical necessity for minimally invasive procedures used to treat low back pain, including basivertebral nerve ablation and percutaneous disc procedures. It applies to Medicare Advantage Plans and Commercial Products, with different authorization and coverage criteria by product.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyMinimally Invasive Procedures for Back Pain
    Policy CodePolicy N/A
    Change TypeRevision
    Effective DateDec 1, 202613d
    Last ReviewAug 19, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization through the online tool for Medicare Advantage thermal destruction of the intraosseous basivertebral nerve.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    CPT codes 62330 and 62331 are identified as new codes effective January 1, 2026.

    CPT code 62287 includes a text revision effective January 1, 2026.

    ≥6 monthsRequired chronic low back pain duration
    ≥6 monthsFailed nonsurgical management
    L3-S1Qualifying vertebral levels
    Up to 4Maximum vertebral bodies treated per procedure
    14Contraindication categories
    2Covered Medicare Advantage codes without prior authorization

    Medical Necessity and Coverage Criteria

    Medicare Advantage Basivertebral Nerve Ablation

    For Medicare Advantage Plans, CPT codes 64628 and 64629 may be considered medically necessary when the medical criteria in the online authorization tool for participating providers are met.

    Medicare Advantage authorization requirement

    • The service is thermal destruction of the intraosseous basivertebral nerve, such as with the Intracept® system, billed with CPT 64628 and/or 64629.
    • The medical criteria in the online authorization tool for participating providers are met.

      Effective 12/1/2026.

    Commercial Basivertebral Nerve Ablation

    For Commercial Products, thermal destruction of the intraosseous basivertebral nerve will be considered medically reasonable and necessary only when ALL selection criteria are met and NONE of the contraindications is present at the time of treatment.

    ALL of the following criteria are required

    • Chronic lumbar back pain of ≥6 months duration that causes functional deficit measured on a pain or disability scale.

      Pain assessment and a disability scale must be obtained at baseline for functional assessment.

    • Documented failure to respond to ≥6 months of nonsurgical management.

      Management may include avoidance of aggravating activities; chiropractic manipulation; physical therapy; cognitive support and recovery reassurance; epidural and/or facet injection therapy; spine biomechanics education; a specific lumbar exercise program; home heat/cold modalities; low-impact aerobic exercise as tolerated; and pharmacotherapy, including non-narcotic analgesics, NSAIDs, muscle relaxants, neuroleptics, and narcotics.

    • Absence of non-vertebrogenic pathology on clinical assessment or radiology studies that could explain the patient's pain, including fracture, tumor, infection, or significant deformity.
    • MRI evidence of Type 1 or Type 2 Modic changes in one or more vertebrae from L3-S1, including associated vertebral endplate inflammation, edema, changes, disruption or fissuring, vascularized fibrous tissue, marrow signal changes, or replacement of normal marrow by fat.

    Noncovered or Not Medically Necessary Disc Procedures

    The following disc procedures are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products because the evidence is insufficient to determine improvement in net health outcomes. TIPs are also noncovered for Medicare Advantage Plans when CMS has determined that they are not reasonable and necessary for treatment of low back pain.

    Noncovered or not medically necessary procedures

    • Percutaneous annuloplasty, including intradiscal electrothermal annuloplasty, intradiscal radiofrequency annuloplasty, or intradiscal biacuplasty, for chronic discogenic back pain.
    • Laser discectomy and radiofrequency coblation (disc nucleoplasty) as techniques of disc decompression and treatment of associated pain.
    • Automated percutaneous discectomy as a technique of intervertebral disc decompression in individuals with back pain and/or radiculopathy related to disc herniation in the lumbar, thoracic, or cervical spine.
    • Percutaneous thermal intradiscal procedures (TIPs) that use radiofrequency or electrothermal energy to apply or create heat and/or disruption within the disc for treatment of low back pain.

    Thermal Destruction of the Intraosseous Basivertebral Nerve

    Thermal destruction of the intraosseous basivertebral nerve is intended for appropriately selected patients with vertebrogenic chronic low back pain and Modic type 1 or 2 changes after conservative treatment has failed.

    Patient selection and procedural requirements

    • Chronic vertebrogenic low back pain has persisted for at least 6 months despite conservative treatment.
    • Modic type 1 or type 2 changes are present in the L3-S1 vertebral endplates on MRI.
    • Non-vertebrogenic causes of pain have been excluded and the patient has undergone multidisciplinary psychological and physical evaluation.
    • The procedure is performed using appropriate patient selection and procedural techniques consistent with the current published literature.
    • Thermal destruction of the intraosseous basivertebral nerve is performed only once per vertebral body from L3-S1 during the individual's lifetime.

    Procedures With Insufficient Evidence

    The following procedures are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products because available evidence is insufficient to determine improvement in net health outcomes.

    Procedures with insufficient evidence

    • Intradiscal electrothermal annuloplasty: randomized controlled trials reported conflicting results; further sham-controlled study in a representative population is needed.
    • Intradiscal radiofrequency annuloplasty: available randomized controlled trials found no evidence of benefit; additional sham-controlled trials are needed.
    • Intradiscal biacuplasty: limited industry-sponsored randomized evidence, with uncertain durability and power; additional sham-controlled trials are needed.
    • Automated percutaneous discectomy: small randomized trials are insufficient to evaluate net health outcomes; well-designed randomized controlled trials are needed.

    Skeletally immature patient; severe cardiac or pulmonary compromise; active systemic or local infection; bleeding diathesis; pregnancy; primary radicular pain into the lower extremities; prior lumbar or lumbosacral surgery at the intended treatment level except qualifying resolved discectomy or laminectomy; primary symptomatic spinal stenosis; osteoporosis, spine fragility fracture, trauma or compression fracture at the treatment level, or spinal cancer; qualifying disc, spondylolisthesis, spondylolysis, or facet abnormalities; BMI >40; advanced generalized systemic disease without a stated treatment objective; active untreated substance abuse; or tobacco use or lack of abstinence documentation.

    title':'Commercial Contraindications to Intraosseous Basivertebral Nerve Ablation

    type':'text'

    Covered and Noncovered Codes

    Potentially covered Medicare Advantage CPTsCPTCovered
    64628CPT identified for thermal destruction of the intraosseous basivertebral nerve; may be considered medically necessary for Medicare Advantage Plans when online authorization-tool criteria are met.
    64629CPT identified for thermal destruction of the intraosseous basivertebral nerve; may be considered medically necessary for Medicare Advantage Plans when online authorization-tool criteria are met.
    Covered CPT Codes for Medicare Advantage Plans; prior authorization not requiredCPTCovered
    62330Decompression, percutaneous, with partial removal of the ligamentum flavum, including laminotomy for access, epidurography, and imaging guidance (ie, ct or fluoroscopy), bilateral; one interspace, lumbar (New Code Effective 1/1/2026)
    62331Decompression, percutaneous, with partial removal of the ligamentum flavum, including laminotomy for access, epidurography, and imaging guidance (ie, ct or fluoroscopy), bilateral; additional interspace(s), lumbar (list separately in addition to code for primary procedure) (New Code Effective 1/1/2026)
    Medically necessary CPT Codes for Medicare Advantage Plans when online authorization criteria are metCPTCovered
    64628Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral
    64629Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure)
    Not Covered for Medicare Advantage PlansmixedNot Covered
    62287Decompression, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle-based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar (Text Revision Effective 1/1/2026)
    S2348Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar
    Medically Necessary CPT Codes for Commercial Products when medical criteria are metCPTCovered
    64628Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral
    64629Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure)
    Not Medically Necessary for Commercial ProductsmixedNot Covered
    62287Decompression, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle-based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar (Text Revision Effective 1/1/2026)
    62330Decompression, percutaneous, with partial removal of the ligamentum flavum, including laminotomy for access, epidurography, and imaging guidance (ie, ct or fluoroscopy), bilateral; one interspace, lumbar (New Code Effective 1/1/2026)
    62331Decompression, percutaneous, with partial removal of the ligamentum flavum, including laminotomy for access, epidurography, and imaging guidance (ie, ct or fluoroscopy), bilateral; additional interspace(s), lumbar (list separately in addition to code for primary procedure) (New Code Effective 1/1/2026)
    S2348Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar
    Not Covered for Medicare Advantage Plans and Not Medically Necessary for Commercial Products when identified as Percutaneous Thermal Intradiscal Procedures (TIPs)CPTNot Covered
    22526Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level
    22527Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; one or more additional levels (List separately in addition to code for primary procedure)
    Chronic low back pain duration
    Pain durationChronic lumbar back pain for ≥6 months
    Clinical impactPain must cause a functional deficit measured on a pain or disability scale
    Applicable serviceCommercial thermal destruction of the intraosseous basivertebral nerve
    Failed nonsurgical management
    Treatment historyDocumented failure to respond to nonsurgical management
    Required duration

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Medicare Advantage Prior Authorization

    Prior authorization is required for Medicare Advantage Plans through the online tool for participating providers before thermal destruction of the intraosseous basivertebral nerve (e.g., Intracept® system).

    Prior Authorization

    Commercial Prior Authorization

    Prior authorization is recommended for Commercial Products before thermal destruction of the intraosseous basivertebral nerve (e.g., Intracept® system).

    Documentation Required

    Meet Online Authorization Criteria

    For Medicare Advantage Plans, CPT 64628 and 64629 may be considered medically necessary only when the medical criteria in the online authorization tool for participating providers are met.

    Clinical Background

    Chronic low back pain may arise from degeneration and inflammation of the vertebral endplates. These changes can activate the basivertebral nerve, producing vertebrogenic pain that is typically midline, deep, aching, or burning and lacks a primary radicular pattern. MRI may demonstrate Modic Type 1 or Type 2 changes adjacent to the affected endplates. Intraosseous basivertebral nerve ablation uses radiofrequency energy under fluoroscopic guidance to create a lesion within the vertebral body.

    Key Terms

    Chronic low back pain (cLBP)
    TermChronic low back pain (cLBP)
    DefinitionPersistent pain in the lumbar region lasting for >12 weeks
    Clinical contextcLBP may result from degeneration and inflammation of the vertebral body or endplates
    Vertebrogenic pain
    DefinitionPain associated with degeneration or inflammation of the vertebral body or endplates
    Typical symptomsMidline, deep, aching, burning, and progressive pain; intermittent electrical shock sensation may occur
    Distinguishing features

    Required Prior Conservative Management

    Documented Failure of Nonsurgical Management

    Before commercial basivertebral nerve ablation, the following conservative-treatment requirement must be documented.

    Nonsurgical management trial: The patient has failed to respond to at least 6 months of nonsurgical management before commercial thermal destruction of the intraosseous basivertebral nerve.≥6 months

    Examples include activity modification, chiropractic manipulation, physical therapy, cognitive support and recovery reassurance, epidural or facet injection therapy, spine biomechanics education, a specific lumbar exercise program, home heat or cold modalities, low-impact aerobic exercise, and pharmacotherapy.

    Failure of Conservative Treatment

    Coverage consideration requires documented failure of conservative treatment for vertebrogenic chronic low back pain.

    Conservative treatment failure: The patient has failed to respond to conservative treatment before basivertebral nerve radiofrequency ablation is considered.

    Treatment Frequency and Quantity Limits

    Frequency limits
    Lifetime frequencyOnce per vertebral body from L3-S1 per lifetime
    Maximum per procedureUp to 4 vertebral bodies
    ServiceThermal destruction or ablation of the intraosseous basivertebral nerve

    Imaging and Procedural Guidance

    Documentation Required

    Confirm qualifying MRI findings

    Obtain MRI evidence before thermal destruction of the intraosseous basivertebral nerve. MRI must demonstrate Type 1 or Type 2 Modic changes in one or more vertebrae from L3-S1 and help exclude non-vertebrogenic pathology explaining the pain.

    Documentation Required

    Use MRI and fluoroscopic guidance

    Support the diagnosis with MRI showing Modic Type 1 or Type 2 changes in the vertebral body endplates. Perform basivertebral nerve ablation with fluoroscopic imaging for procedural guidance.

    • MRI: document the qualifying Modic changes.
    • Procedure: use fluoroscopic imaging for guidance.

    Excluded and Noncovered Services

    The following services are not covered: percutaneous annuloplasty, including intradiscal electrothermal annuloplasty, intradiscal radiofrequency annuloplasty, and intradiscal biacuplasty; laser discectomy; radiofrequency coblation or disc nucleoplasty; and automated percutaneous discectomy. Percutaneous thermal intradiscal procedures for low back pain are also noncovered for Medicare Advantage Plans.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyMinimally Invasive Procedures for Back Pain
    Policy CodePolicy N/A
    Change TypeRevision
    Effective DateDec 1, 202613d
    Last ReviewAug 19, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization through the online tool for Medicare Advantage thermal destruction of the intraosseous basivertebral nerve.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCovered and Noncovered CodesAuthorization, Documentation, and Denial RisksClinical BackgroundKey TermsRequired Prior Conservative ManagementTreatment Frequency and Quantity LimitsImaging and Procedural GuidanceExcluded and Noncovered Services
    The individual has undergone careful screening, evaluation, and diagnosis by a multidisciplinary team before thermal destruction of the intraosseous basivertebral nerve.

    Screening must include psychological and physical evaluation. Documentation of the history and screening must be available in the patient chart if requested.

  1. NONE of the following contraindications may be present

    • Skeletally immature patient (≤18 years old).
    • Severe cardiac or pulmonary compromise.
    • Active systemic infection or local infection at the intended treatment level.
    • Bleeding diathesis.
    • Pregnancy.
    • Primary radicular pain into the lower extremities, defined as nerve pain following a dermatomal distribution that correlates with nerve compression on imaging.
    • Previous lumbar or lumbosacral spine surgery at the intended treatment level, except discectomy or laminectomy performed >6 months before BVN nerve ablation when radicular pain has resolved.
    • Primary symptomatic lumbar or lumbosacral spinal stenosis, defined as neurogenic claudication confirmed by imaging.
    • Diagnosed osteoporosis (T-score of -2.5 or less), history of spine fragility fracture, trauma or compression fracture at the intended treatment level, or spinal cancer.
    • Radiographic evidence correlating with predominant physical complaints of lumbar/lumbosacral disc extrusion or protrusion >5 mm at L3-S1; spondylolisthesis >2 mm at any level; spondylolysis at L3-S1; or facet arthrosis/effusion correlated with facet-mediated pain at L3-S1.
    • BMI >40.
    • Advanced generalized systemic disease that limits quality-of-life improvement, unless the objective of treatment is specifically stated.
    • Active, untreated substance abuse disorder.
    • Tobacco use or lack of clinical documentation, based on attestation, that the individual has been abstinent from tobacco use.
  2. Noncovered for Medicare Advantage Plans based on the Centers for Medicare and Medicaid Services determination that TIPs are not reasonable and necessary.

    Up to 4 vertebral bodies may be treated during one procedure.

    Laser discectomy: evidence consists primarily of observational studies, case series, and uncontrolled studies; the lack of well-designed controlled trials limits interpretation.
  3. Disc nucleoplasty with radiofrequency coblation: randomized trials are limited by lack of blinding, inadequate control conditions or data reporting, low enrollment, and early termination; high-quality randomized trials with adequate follow-up are needed.
  4. ≥6 months
    ExamplesActivity modification, physical therapy, exercise, injections, modalities, and pharmacotherapy
    Qualifying Modic changes
    MRI findingModic Type 1 or Type 2 changes
    Vertebral locationIn 1 or more vertebrae from L3-S1
    Imaging purposeSupports vertebrogenic pain associated with endplate inflammation, edema, or fatty marrow replacement
    BMI contraindication
    ContraindicationBMI greater than 40
    Threshold>40
    ApplicationMust be absent at the time of intraosseous basivertebral nerve treatment
    Osteoporosis contraindication
    ConditionDiagnosed osteoporosis
    T-score threshold-2.5 or less
    Coverage implicationOsteoporosis at this threshold is a contraindication to treatment
    Disc extrusion or protrusion contraindication
    Radiographic findingLumbar or lumbosacral disc extrusion or protrusion
    Size threshold>5 mm
    Applicable levelsL3-S1
    Spondylolisthesis contraindication
    Radiographic findingLumbar or lumbosacral spondylolisthesis
    Displacement threshold>2 mm
    Applicable locationAny level
    Treatment frequency
    Lifetime limitOnce per vertebral body from L3-S1 per lifetime
    Per-procedure limitUp to 4 vertebral bodies may be treated during 1 procedure
    ProcedureThermal destruction or ablation of the intraosseous basivertebral nerve
    Radiofrequency treatment parameters
    Energy modalityRadiofrequency energy
    Temperature85 degrees Celsius
    Application duration15 minutes
    Conservative treatment
    Treatment requirementFailure to respond to conservative treatment
    Minimum durationAt least 6 months
    Applicable conditionVertebrogenic chronic low back pain before BVN radiofrequency ablation
    Chronic low back pain definition
    DefinitionPersistent pain in the lumbar region
    Duration threshold>12 weeks
    TermChronic low back pain (cLBP)
    Supported vertebral levels
    Supported anatomyVertebral body endplates
    Supported levelsL3-S1
    Clinical associationModic Type 1 or Type 2 changes corresponding to vertebrogenic low back pain
    • 64628: Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral.
    • 64629: Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral.
    Documentation Required

    Meet Commercial Medical Criteria

    For Commercial Products, CPT 64628 and 64629 are considered medically necessary only when the applicable medical criteria are met.

    • 64628: Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral.
    • 64629: Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral.
    Step Therapy

    Document Six-Month Conservative Treatment Failure

    Document a failed trial of at least six months of nonsurgical management before thermal destruction of the intraosseous basivertebral nerve.

    • Management may include avoidance of aggravating activities, chiropractic manipulation, physical therapy, cognitive support and recovery reassurance, epidural or facet injection therapy, spine biomechanics education, a specific lumbar exercise program, home heat/cold modalities, low-impact aerobic exercise as tolerated, and pharmacotherapy such as non-narcotic analgesics, NSAIDs, muscle relaxants, neuroleptics, or narcotics.
    Documentation Required

    Required Clinical Documentation

    Maintain clinical documentation supporting the diagnosis, treatment history, and medical-necessity determination. Baseline pain and disability scales must be obtained for functional assessment, and the chart must document multidisciplinary screening and evaluation, including psychological and physical assessment, when requested.

    • Chronic lumbar back pain must be present for at least six months and cause functional deficit measured on a pain or disability scale.
    • Document clinical assessment and radiology findings showing no non-vertebrogenic source such as fracture, tumor, infection, or significant deformity.
    • Document Type 1 or Type 2 Modic changes on MRI at one or more vertebral bodies from L3-S1.
    • Document treatment history and the multidisciplinary diagnostic and screening evaluation.
    Documentation Required

    Confirm Contraindications and Tobacco Status

    Before treatment, document that no listed contraindication is present and include the required tobacco-abstinence attestation when applicable.

    • Contraindications include skeletal immaturity; severe cardiac or pulmonary compromise; active systemic or local infection; bleeding diathesis; pregnancy; primary radicular pain; prior surgery at the intended level except qualifying discectomy/laminectomy; symptomatic lumbar or lumbosacral stenosis; osteoporosis, fragility or compression fracture, or spinal cancer; correlating disc extrusion/protrusion greater than 5 mm, spondylolisthesis greater than 2 mm, spondylolysis, or facet arthrosis/effusion; BMI greater than 40; advanced generalized systemic disease without a stated treatment objective; and active untreated substance-use disorder.
    • The individual must not be a tobacco user, and clinical documentation must attest to tobacco abstinence.
    • Thermal destruction may be performed only once per vertebral body from L3-S1 per lifetime; up to four vertebral bodies may be treated in one procedure.
    Billing Rule

    Advance Written Member Agreement

    If proceeding with treatment that is not medically necessary or is a medically necessary service excluded from the member’s benefits, obtain the member’s written agreement in advance to continue treatment at the member’s own expense. Do not charge the member without this advance written agreement.

    • Refer to the applicable participation agreement for member billing provisions.
    Denial Risk

    Commercial Denial: Criteria or Contraindications

    For Commercial Products, failure to meet any required selection criterion or the presence of any contraindication means the procedure does not meet medical-necessity requirements and may be denied.

    • Required criteria include at least six months of chronic lumbar pain with functional deficit, failure of at least six months of nonsurgical management, no alternative non-vertebrogenic pain source, Modic Type 1 or Type 2 changes at L3-S1, and multidisciplinary screening and evaluation.
    • All listed contraindications must be absent, including the applicable tobacco-abstinence documentation.
    Denial Risk

    Percutaneous Disc Procedures: Coverage Warning

    Percutaneous disc procedures listed below are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products because evidence is insufficient to establish improved net health outcomes.

    • Percutaneous annuloplasty, including intradiscal electrothermal annuloplasty, intradiscal radiofrequency annuloplasty, and intradiscal biacuplasty.
    • Laser discectomy and radiofrequency coblation (disc nucleoplasty) for disc decompression or associated pain.
    • Automated percutaneous discectomy for intervertebral disc decompression.
    • CPT 62287 and HCPCS S2348 are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products.
    • CPT 62330 and 62331 are not medically necessary for Commercial Products; CPT 62330 and 62331 are covered for Medicare Advantage Plans without prior authorization as specified in the policy.
    Denial Risk

    Denial Risk: BVN Selection Criteria

    Thermal destruction of the intraosseous basivertebral nerve for vertebrogenic chronic low back pain may be denied when the individual does not satisfy the evidence-based BVN ablation selection criteria.

    • Appropriate selection includes vertebrogenic chronic low back pain associated with Modic Type 1 or Type 2 changes in the L3-S1 vertebral endplates.
    • The individual must have failed conservative treatment for at least six months and meet the policy’s clinical, radiologic, functional, screening, and contraindication requirements.
    • Use the applicable plan-specific authorization and medical-necessity requirements before billing CPT 64628 or 64629.
    Denial Risk

    Denial Risk: Insufficient Evidence or Excluded Procedures

    Intradiscal electrothermal annuloplasty, intradiscal radiofrequency annuloplasty, intradiscal biacuplasty, automated percutaneous discectomy, laser discectomy, and disc nucleoplasty with radiofrequency coblation may be denied because available evidence is insufficient to determine improvement in net health outcomes.

    • The evidence is limited by conflicting or negative randomized-trial results, small or inadequately controlled studies, nonrandomized designs, confounding, and insufficient follow-up.
    • High-quality sham-controlled or randomized trials with adequate follow-up are needed to establish benefit.
    Note

    Verify Member Benefits and Coverage

    Member-specific benefits and exclusions control coverage. This policy is informational and does not guarantee payment; the member’s subscriber agreement or certificate and the employer agreement supersede the policy where applicable.

    • Verify eligibility and benefits through the provider call center.
    • Follow the applicable member-specific benefit documents and participation agreement.
    • A service may be non-covered even when it is medically necessary under the policy.
    Generally lacks radicular expression, lower-extremity weakness, or sensory deficits
    Modic changes
    DefinitionMRI signal changes in vertebral body bone marrow adjacent to degenerative endplates
    Type 1Indicates inflammation and edema
    Type 2Occurs with marrow ischemia and conversion of red hematopoietic marrow to yellow fatty marrow
    Percutaneous thermal intradiscal procedures (TIPs)
    DefinitionPercutaneous intradiscal techniques using a catheter or probe under fluoroscopic guidance
    Energy usedRadiofrequency or electrothermal energy
    PurposeApply heat or disruption within disc material for coagulation, decompression, or pain relief
    Basivertebral nerve (BVN)
    AnatomyA sensory nerve entering the posterior vertebral body
    DistributionBranches to the superior and inferior vertebral endplates
    Treatment relevanceTransmits pain signals associated with vertebrogenic pain and is treated with radiofrequency ablation
    Chronic low back pain (cLBP)
    TermChronic low back pain (cLBP)
    DurationPersistent lumbar pain lasting for more than 12 weeks
    EtiologyMay be associated with vertebral body or endplate degeneration and inflammation
    Vertebrogenic pain
    DefinitionLow back pain associated with degeneration or inflammation of the vertebral body endplates
    Pain transmissionPain signals are transmitted by the basivertebral nerve
    Typical patternMidline, deep, aching or burning pain without a primary radicular pattern
    Modic changes
    DefinitionMRI signal changes in vertebral body bone marrow adjacent to degenerative endplates
    Modic Type 1Indicates inflammation and edema
    Modic Type 2Reflects marrow ischemia with conversion to yellow fatty marrow
    Intraosseous basivertebral nerve ablation
    DefinitionThermal destruction of the intraosseous basivertebral nerve using radiofrequency energy
    Imaging guidancePerformed with fluoroscopic imaging
    Treatment targetThe basivertebral nerve within the vertebral body
    At least 6 months